• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型化合物在细胞培养中抑制 SARS-CoV-2 复制。

New Chemicals Suppressing SARS-CoV-2 Replication in Cell Culture.

机构信息

Dimonta Ltd., 15 Nagornaya Str., Bldg 8, 117186 Moscow, Russia.

Research Computing Center, Lomonosov Moscow State University, Leninskie Gory, 1, Building 4, 119234 Moscow, Russia.

出版信息

Molecules. 2022 Sep 5;27(17):5732. doi: 10.3390/molecules27175732.

DOI:10.3390/molecules27175732
PMID:36080498
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9457583/
Abstract

Candidates to being inhibitors of the main protease (Mpro) of SARS-CoV-2 were selected from the database of Voronezh State University using molecular modeling. The database contained approximately 19,000 compounds represented by more than 41,000 ligand conformers. These ligands were docked into Mpro using the SOL docking program. For one thousand ligands with best values of the SOL score, the protein-ligand binding enthalpy was calculated by the PM7 quantum-chemical method with the COSMO solvent model. Using the SOL score and the calculated protein-ligand binding enthalpies, eighteen compounds were selected for the experiments. Several of these inhibitors suppressed the replication of the coronavirus in cell culture, and we used the best three among them in the search for chemical analogs. Selection among analogs using the same procedure followed by experiments led to identification of seven inhibitors of the SARS-CoV-2 replication in cell culture with EC50 values at the micromolar level. The identified inhibitors belong to three chemical classes. The three inhibitors, 4,4-dimethyldithioquinoline derivatives, inhibit SARS-CoV-2 replication in Vero E6 cell culture just as effectively as the best published non-covalent inhibitors, and show low cytotoxicity. These results open up a possibility to develop antiviral drugs against the SARS-CoV-2 coronavirus.

摘要

候选者作为抑制剂的主要蛋白酶(Mpro)的 SARS-CoV-2 是从数据库的沃罗涅日国立大学使用分子建模。数据库包含了大约 19000 种化合物,代表了超过 41000 个配体构象。这些配体被用于 Mpro 的 SOL 对接程序。对于一千个配体的最佳值的 SOL 评分,蛋白-配体结合焓的计算方法的 PM7 量子化学方法与 COSMO 溶剂模型。使用 SOL 评分和计算的蛋白-配体结合焓,十八种化合物被选为实验。这些抑制剂中的几种抑制了冠状病毒在细胞培养物中的复制,我们使用其中最好的三种在寻找化学类似物。使用相同程序的类似物选择和实验导致了在细胞培养物中鉴定出七种 SARS-CoV-2 复制的抑制剂,EC50 值在微摩尔水平。鉴定出的抑制剂属于三个化学类别。这三种抑制剂,4,4-二甲基二硫代喹啉衍生物,在 Vero E6 细胞培养物中抑制 SARS-CoV-2 复制的效果与最好的已发表的非共价抑制剂一样有效,且细胞毒性较低。这些结果为开发针对 SARS-CoV-2 冠状病毒的抗病毒药物提供了可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/c2a0f676b578/molecules-27-05732-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3cf2a05e272d/molecules-27-05732-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/7c0124502b13/molecules-27-05732-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/84994c032e26/molecules-27-05732-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3ce9277c0542/molecules-27-05732-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3578bd3b898f/molecules-27-05732-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/a86d6403b5b7/molecules-27-05732-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/f1267d2b0b91/molecules-27-05732-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/b4a745ad498e/molecules-27-05732-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3038e6870d06/molecules-27-05732-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/1491b5f99fd2/molecules-27-05732-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/a8fbf6635252/molecules-27-05732-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/c2a0f676b578/molecules-27-05732-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3cf2a05e272d/molecules-27-05732-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/7c0124502b13/molecules-27-05732-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/84994c032e26/molecules-27-05732-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3ce9277c0542/molecules-27-05732-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3578bd3b898f/molecules-27-05732-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/a86d6403b5b7/molecules-27-05732-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/f1267d2b0b91/molecules-27-05732-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/b4a745ad498e/molecules-27-05732-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/3038e6870d06/molecules-27-05732-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/1491b5f99fd2/molecules-27-05732-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/a8fbf6635252/molecules-27-05732-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aeb6/9457583/c2a0f676b578/molecules-27-05732-g010.jpg

相似文献

1
New Chemicals Suppressing SARS-CoV-2 Replication in Cell Culture.新型化合物在细胞培养中抑制 SARS-CoV-2 复制。
Molecules. 2022 Sep 5;27(17):5732. doi: 10.3390/molecules27175732.
2
[Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].基于新型冠状病毒主要蛋白酶抑制剂的抗病毒药物研发
Biomed Khim. 2021 May;67(3):259-267. doi: 10.18097/PBMC20216703259.
3
Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M.基于结构的虚拟筛选、计算机对接、ADME 性质预测和分子动力学研究,以鉴定针对 SARS-CoV-2 M 的潜在抑制剂。
Mol Divers. 2022 Jun;26(3):1645-1661. doi: 10.1007/s11030-021-10298-0. Epub 2021 Sep 4.
4
In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.计算机模拟评估菲律宾天然产物对 SARS-CoV-2 主蛋白酶的抑制作用。
J Mol Model. 2022 Oct 7;28(11):345. doi: 10.1007/s00894-022-05334-1.
5
In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.通过分子对接、MMGBSA 预测结合能计算和分子动力学模拟,从计算机上鉴定潜在的关键 SARS-CoV-2 3CL 水解酶(Mpro)抑制剂。
PLoS One. 2020 Jul 24;15(7):e0235030. doi: 10.1371/journal.pone.0235030. eCollection 2020.
6
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.
7
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
8
Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses.探索新型地衣化合物作为 SARS-CoV-2 Mpro 抑制剂:基于配体的设计、分子动力学和 ADMET 分析。
Appl Biochem Biotechnol. 2022 Dec;194(12):6386-6406. doi: 10.1007/s12010-022-04103-3. Epub 2022 Aug 3.
9
Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.SARS-CoV-2 编码的 M 蛋白酶抑制剂的发现。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00872-20.
10
Solanaceae Family Phytochemicals as Inhibitors of 3C-Like Protease of SARS-CoV-2: An In Silico Analysis.茄科植物化学成分作为 SARS-CoV-2 3C 样蛋白酶抑制剂的计算机模拟分析。
Molecules. 2022 Jul 25;27(15):4739. doi: 10.3390/molecules27154739.

引用本文的文献

1
Design, Synthesis, and Evaluation of New Hybrid Derivatives of 5,6-Dihydro-4-pyrrolo[3,2,1-]quinolin-2(1)-one as Potential Dual Inhibitors of Blood Coagulation Factors Xa and XIa.新型 5,6-二氢-4-吡咯并[3,2,1-]喹啉-2(1H)-酮类杂合衍生物的设计、合成与评价作为潜在的凝血因子 Xa 和 XIa 的双重抑制剂。
Molecules. 2024 Jan 11;29(2):373. doi: 10.3390/molecules29020373.

本文引用的文献

1
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.S-217622 的发现:一种非共价的口服 SARS-CoV-2 3CL 蛋白酶抑制剂临床候选药物,用于治疗 COVID-19。
J Med Chem. 2022 May 12;65(9):6499-6512. doi: 10.1021/acs.jmedchem.2c00117. Epub 2022 Mar 30.
2
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.利用小分子体外重新利用筛选法鉴定严重急性呼吸综合征冠状病毒2 3C样蛋白酶(SARS-CoV-2 3CL-Pro)酶活性抑制剂
ACS Pharmacol Transl Sci. 2021 Mar 11;4(3):1096-1110. doi: 10.1021/acsptsci.0c00216. eCollection 2021 Jun 11.
3
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.
口服蛋白酶抑制剂(PF-07321332)可保护叙利亚仓鼠免受高关注变异 SARS-CoV-2 病毒株的感染。
Nat Commun. 2022 Feb 15;13(1):719. doi: 10.1038/s41467-022-28354-0.
4
Quantum-Chemical Quasi-Docking for Molecular Dynamics Calculations.用于分子动力学计算的量子化学准对接
Nanomaterials (Basel). 2022 Jan 15;12(2):274. doi: 10.3390/nano12020274.
5
Design and Evaluation of Bispidine-Based SARS-CoV-2 Main Protease Inhibitors.基于联吡啶的新型冠状病毒2型主要蛋白酶抑制剂的设计与评估
ACS Med Chem Lett. 2021 Sep 29;13(1):140-147. doi: 10.1021/acsmedchemlett.1c00299. eCollection 2022 Jan 13.
6
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
7
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.静脉注射冠状病毒 3CL 蛋白酶抑制剂的临床前特征,用于治疗 COVID19 的潜在药物。
Nat Commun. 2021 Oct 18;12(1):6055. doi: 10.1038/s41467-021-26239-2.
8
Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.通过计算机设计和逐步的生物学特征分析鉴定一种双重作用的 SARS-CoV-2 蛋白酶抑制剂。
Eur J Med Chem. 2021 Dec 15;226:113863. doi: 10.1016/j.ejmech.2021.113863. Epub 2021 Sep 22.
9
Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.发现胡桃醌及其衍生物是强效 SARS-CoV-2 主蛋白酶抑制剂。
Eur J Med Chem. 2021 Dec 5;225:113789. doi: 10.1016/j.ejmech.2021.113789. Epub 2021 Aug 18.
10
An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19.计算机辅助药物设计及其在 COVID-19 中的应用的最新综述。
Biomed Res Int. 2021 Jun 24;2021:8853056. doi: 10.1155/2021/8853056. eCollection 2021.